Malignant Melanoma of Skin Stage III, Metastatic Melanoma
Conditions
Keywords
B-Raf, inoperable stage III melanoma, metastatic stage IV melanoma,
Brief summary
The purpose of this research study is to test an experimental combination of drugs to determine if they can cause shrinkage or even complete disappearance of your melanoma. The two drugs being tested in combination are Rituxan and Abraxane
Detailed description
Rituxan and Abraxane are approved for the treatment of other cancers, but not for melanoma. Candidates for this study have melanoma that has spread to their lymph nodes or internal organs and that cannot be removed by a surgical procedure. The safety of this combination of drugs will also be looked at throughout this study. Rituxan will be administered IV at weeks 1 and 3 of each cycle. Abraxane will be administered IV weekly for 3 consecutive weeks. This is followed by 1 week of rest after which, the cycle is repeated. Following the second cycle, there will be a 4-week period of rest. Evaluation of response will occur on day 71 +/-3 days. If either disease stabilization or clear evidence of clinical response is observed two additional cycles of treatment will be administered. Lesions will be measured on the scan (CT or PET/CT), x-ray
Interventions
DRUGRituxan
The dose of Rituxan is 375 mg/m2¬ administered as an IV infusion during weeks 1 & 3 (days 1 & 15)Abraxane will be administered at a fixed dose of 100 mg/m2 as an IV infusion weekly for three weeks in a row followed by one week of rest
Sponsors
California Cancer Assocaties for Research & Excellence
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have inoperable stage III and IV melanoma. Patients will be included in the trial based on the following criteria: Patients previously treated with no more than 1 non-abraxane containing chemotherapy regimen or patients with the B-Raf mutation, who have received vemurafenib or the combination of Dabrafinib and trametinib (or similar compound on clinical trial) and progressed, who have documented surgically inoperable stage III or IV metastatic melanoma on pathologic examination of tissue. Previous treatment with immunotherapy is allowed. Patients who have been treated with either immunotherapy or chemotherapy must have be either 4 weeks from their last treatment or have fully recovered from all previous treatment. Measurable or evaluable non-CNS disease required as defined: * Uni-dimensionally measurable lesion as determined by physical exam, X-ray, CT scan, MRI, or other radiographic procedure. * Lesion that can be seen on a radiologic test but is not uni-dimensionally measurable * Previously irradiated lesion allowed only with documentation of progression if no other metastatic site present. No active brain metastases Patients with previously treated brain metastases that have responded to therapy will be allowed on study assuming there is measurable disease outside of the CNS. Active therapy for the CNS disease must be completed a minimum of 3 weeks for chemotherapy and 6 weeks for radiation therapy (prior to enrollment on this study). Prior/ Concurrent therapy Biologic therapy No concurrent biological therapy with the exception of growth factors for anemia, neutropenia or thrombocytopenia. Chemotherapy No greater than 1 previous non-abraxane containing chemotherapy treatment allowed Radiotherapy At least 6 weeks since completion of radiotherapy Patient characteristics Age and ability to give informed consent Patients must be 18 years of age or older. Patients must have the ability to give informed consent. Performance status ECOG 0-2 Life expectancy of at least 3 months General Medical Concerns: * Normal organ function, except if abnormal due to tumor involvement. * Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months after completion of treatment. * Subject has provided written informed consent. Rituximab-Specific Concerns: * ANC: \> 1200/mm3 * Platelets: \> 100,000/mm3 * Hemoglobin: \> 9 gm/dL * Adequate renal function as indicated by serum creatinine measurement \< 1.5 x the upper limit of normal or GFR \> 50 ml/min. * Adequate liver function, as indicated by bilirubin \< 3.0 * AST or ALT \<2x Upper Limit of Normal unless related to primary disease. * AST or ALT \<5x Upper limit of Normal if evidence of liver metastasis.
Exclusion criteria
* Life expectancy less than 3 months Untreated brain metastasis Previous treatment with Abraxane containing regimen
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall response as determined by a Percent change (%) in the sum of the diameters of target lesions. | baseline-12 weeks | Evaluation of response (Progression Free and overall survival will be determined by measuring and recording the largest diameter of a lesion. Add these values together and record the value as the sum of the largest diameters.The percent change will be obtained according to the following formula: Percent change = sum of the longest diameter at 12weeks X 100 Sum of the longest diameters pre treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response rate as Percent change in diameter (mm) of target lesions | 2 years | Overall response rate ( complete response + Partial response) will be determined by the disappearance of lesions or a reduction of target lesions in short axis to \<10mm (CR) + at least a 30% decrease in the sum of the longest diameters of the target lesions (PR). |
Countries
United States
Contacts
Primary ContactEdward F McClay, MD
Backup ContactBeth Kimball, OCN, RN
Outcome results
None listed